R-CVP

DRUG3 trials

Sponsors

Spectrum Pharmaceuticals, Inc, Fondazione Italiana Linfomi - ETS, AstraZeneca

Conditions

Follicular LymphomaLymphoma, FollicularUntreated Follicular Lymphoma

Phase 3

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

TerminatedNCT00384111

Spectrum Pharmaceuticals, IncFollicular Lymphoma, Lymphoma, Follicular

Start: 2006-10-31End: 2008-11-30Updated: 2022-01-14

Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma

Fondazione Italiana Linfomi - ETSFollicular Lymphoma

Start: 2005-12-31End: 2014-03-31Updated: 2011-02-15

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

RecruitingNCT06549595

AstraZenecaUntreated Follicular Lymphoma

Start: 2024-08-07End: 2031-11-26Target: 1018Updated: 2026-03-18

Related Papers

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood2025-11-03

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Blood2025-11-03

POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL.

Hematological Oncology2017-06-014 citations

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study

Haematologica2015-01-167 citations

Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial

Clinical Cancer Research2014-10-14113 citations

Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.

Journal of Clinical Oncology2014-05-201 citations

The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).

2014-01-1058 citations